Physician profile
Noemi Baffy
NPI 1164710075
$1,136.09
in general payments reported to CMS, 2019-2025
17 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.22 · 2021: $42.16 · 2022: $89.09 · 2023: $285 · 2024: $269 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.46 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $235.37 | 2025 | |
| Genzyme Corporation | $202.47 | 2022-2025 | |
| Janssen Biotech, INC. | $133.83 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $130.42 | 2023-2025 | Skyrizi |
| Celgene Corporation | $62.77 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $56.43 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $54.64 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $49.84 | 2023 | Zeposia |
| Boston Scientific Corporation | $42.16 | 2021 | |
| Pfizer INC. | $40.00 | 2024 | |
| Covidien Lp | $30.22 | 2020 | |
| Novo Nordisk INC | $28.08 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $18.65 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $15.34 | 2023 | Entyvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.71 | 2023 | Dificid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noemi Baffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.